Biograil Raises €20 Million to Push Oral Biologic Delivery Into Clinics
Copenhagen's Biograil raises €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its capsule-based BIONDD® oral delivery platform toward Phase 1 trials.
Topic
Biotech Funding
Topic
Biotech Funding
Alethio Therapeutics Raises €80.46M Series A for Blood Cancer Drugs
Oxford spin-out Alethio Therapeutics closed an oversubscribed €80.46M Series A led by Sofinnova Partners and RA Capital to advanc…
Biograil Raises €20 Million to Move Oral Drug Platform Toward Trials
Copenhagen-based Biograil raised €20 million to advance its capsule-based BIONDD oral delivery platform through preclinical work…
Biograil closes €20 million to replace injections with swallowable drug device
Copenhagen's Biograil raised €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its swallowable BIONDD device…
Star Therapeutics Raises $200 Million to Push Preclinical Drugs Into Clinic
Star Therapeutics raised $200 million co-led by OrbiMed and Janus Henderson, months after Incyte paid up to $2 billion for its Ve…
Trior Raises $25 Million in Series C for ADC Platforms
Trior raised $25 million in two Series C closings, lifting cumulative funding to $58 million. The biotech is funding ADC platform…
Nouscom Banks $135 Million to Advance Cancer Vaccine NOUS-209
Nouscom has raised $135 million to advance NOUS-209, its lead off-the-shelf cancer vaccine — one of the larger biotech rounds of…
OrbiMed Raises $3 Billion Across Global and Asia Healthcare Funds
OrbiMed raised $3 billion across a global healthcare fund and an Asia-focused vehicle, per Pulse 2.0, giving the healthcare speci…
Alphabet's Isomorphic Labs Targets $40 Billion Valuation in New Round
Isomorphic Labs, Alphabet's drug-discovery company, is seeking a valuation of at least $40 billion in a new funding round, accord…
Link Cell Therapies Adds $30M, Expands Series A to $90M
Link Cell Therapies has secured an additional $30 million, bringing its Series A round to $90 million, FinSMEs reports, in a sign…
Enveda Raises $311 Million in Series E Round
AI-driven natural-medicine biotech Enveda has raised $311 million in a Series E round, one of the larger late-stage biotech finan…